XML 11 R4.htm IDEA: XBRL DOCUMENT v3.26.3
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Operating expenses        
Research and development $ 17,761 $ 14,969 $ 53,188 $ 48,776
General and administrative 3,911 4,101 12,534 12,991
Total operating expenses 21,672 19,070 65,722 61,767
Loss from operations (21,672) (19,070) (65,722) (61,767)
Other income, net 714 1,047 2,694 3,680
Change in fair value of warrant liabilities 17,025 564 (11,560) 22,917
Net loss (3,933) (17,459) (74,588) (35,170)
Other comprehensive loss:        
Unrealized gain (loss) on available-for-sale securities, net (12) 57 (150) (17)
Comprehensive loss $ (3,945) $ (17,402) $ (74,738) $ (35,187)
Basic net loss per share of common stock $ (0.03) $ (0.21) $ (0.63) $ (0.42)
Diluted net loss per share of common stock $ (0.03) $ (0.21) $ (0.63) $ (0.42)
Weighted-average common shares outstanding, basic 114,722,339 77,156,068 113,601,123 77,146,407
Weighted-average common shares outstanding, diluted 114,722,339 77,156,068 113,601,123 77,146,407
Series X and Series X1 Non-voting Convertible Preferred Stock [Member]        
Other comprehensive loss:        
Basic net loss per share of common stock $ (1.83) $ (11.61) $ (34.84) $ (23.4)
Diluted net loss per share of common stock $ (1.83) $ (11.61) $ (34.84) $ (23.4)
Weighted-average common shares outstanding, basic 80,222 114,508 96,076 114,508
Weighted-average common shares outstanding, diluted 80,222 114,508 96,076 114,508